• Investors may be wondering if Soleno Therapeutics at around US$52.94 is priced attractively after its past swings, or if most of the opportunity is already reflected in the stock.
• The share price shows a mixed picture, with returns of 0.3% over 7 days, 1.3% over 30 days, 12.2% year to date, a 29.1% decline over the last year, and a very large gain over 3 years that is more than 10x.
• Recent headlines around Soleno Therapeutics have focused on its progress as a clinical stage biopharmaceutical company, as well as investor interest in how its pipeline could translate into long term value. This context helps explain why the stock has seen both sharp gains over several years and setbacks within the last 12 months as expectations and perceived risks shifted.
• On Simply Wall St's valuation checks, Soleno Therapeutics currently has a value score of 2 out of 6, which sets up a closer look at how traditional metrics, discounted cash flow models, and an even broader way of thinking about valuation all fit together later in this article.

Soleno Therapeutics scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Soleno Therapeutics Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting future cash flows and then discounting them back to today in dollar terms. It is essentially asking what those future dollars are worth right now.

For Soleno Therapeutics, the 2 Stage Free Cash Flow to Equity model starts with last twelve month free cash flow of about $46.50 million, then uses analyst estimates out to 2030 and further extrapolated figures from Simply Wall St. By 2030, projected free cash flow is $794.47 million, with annual figures between 2026 and 2035 all remaining below $2 billion and gradually rising according to the model assumptions.

After discounting these projected cash flows back to today, the model arrives at an estimated intrinsic value of about $442.21 per share. Compared with the recent share price of about $52.94, this framework suggests the stock is around 88.0% undervalued based on these inputs and assumptions.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Soleno Therapeutics is undervalued by 88.0%. Track this in your watchlist or portfolio, or discover 44 more high quality undervalued stocks.

Approach 2: Soleno Therapeutics Price vs Earnings

P/E is a useful yardstick for profitable companies because it links what you pay for each share to the earnings that support that share price. Higher expected growth and lower perceived risk can justify a higher “normal” P/E, while slower growth or higher risk usually points to a lower one.

Soleno Therapeutics currently trades on a P/E of about 133.7x. That is well above the Biotechs industry average P/E of around 17.8x and also higher than the peer group average of about 26.8x. To go further than simple comparisons, Simply Wall St calculates a proprietary “Fair Ratio”, which is the P/E that might be expected given factors such as earnings growth, industry, profit margins, market cap and company specific risks.

Because the Fair Ratio blends these fundamentals, it can give a more tailored view than just comparing Soleno with the broad industry or a handful of peers that may have very different profiles. For Soleno, the Fair Ratio is 25.8x, which is far below the current P/E of 133.7x. On this metric, the stock screens as overvalued.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Soleno Therapeutics Narrative

Earlier there was mention of an even better way to understand valuation. Narratives bring that idea to life by letting you connect your view of Soleno Therapeutics, for example whether it is closer to the bullish fair value of about US$143.71 or the bearish fair value of about US$83.36, with your own revenue, earnings and margin assumptions. You can then turn that story into a forecast and fair value on Simply Wall St's Community page, and keep it updated as news or earnings arrive so you can compare Fair Value to the live share price and decide whether the stock sits in your personal buy, hold or sell zone.

Do you think there's more to the story for Soleno Therapeutics? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.